Document:

EXHIBIT 10.24

 

BUSINESS MANAGEMENT AGREEMENT

 

THIS BUSINESS MANAGEMENT AGREEMENT
(“Agreement”), made this _____ day of February, 2014 by and among:

 

MAIN AVENUE PHARMACY, INC., a New Jersey corporation
with a business location at 1094 Main Avenue, Clifton, NJ 07011 (hereinafter “Pharmacy”);

 

AND

 

SCRIPSAMERICA, INC., a Delaware corporation with its
principal offices located at 843 Persimmon Lane, Langhorne, PA 19047 (hereinafter “Scrips”)

 

AND

 

IMPLEX CORPORATION, a Nevada corporation with its registered
office located at 4650 Wedekind Road, Suite 2, Sparks, NV 89431-7722 (hereinafter “Implex”)

 

WITNESSETH THAT:

 

WHEREAS, Implex is entering into a certain
agreement to purchase, over time, 100% of the issued and outstanding capital stock of Pharmacy, and the current owner of Pharmacy,
Dmitriy Naydenko, desires to discontinue his business management functions, while continuing his legal responsibilities with respect
to the compounding pharmacy operations pending completion of the sale/purchase and the licensing of Implex, but Implex is not in
a position to provide business management functions, and Implex desires to secure third-party business management for the Pharmacy;

 

WHEREAS, Scrips is able to provide the business
management for Pharmacy, including financial support for Pharmacy’s day-to-day operations and both Implex and Pharmacy desire
to secure such services;

 

WHEREAS, the parties have discussed the
situation and have negotiated and reached certain understandings, for which they desire a document to formalize and evidence such
understandings;

 

NOW, THEREFORE, intending to be legally bound, and in consideration of the mutual promises and covenants contained
herein, the parties have agreed, and do hereby agree, as follows:

 

1. ENGAGEMENT OF SCRIPS. (a) Implex, under the terms
and conditions of this Agreement, hereby appoints, hires and engages Scrips to manage the day-to-day business operations of Pharmacy.

 

(b) Pharmacy, under the terms and conditions
of this Agreement, hereby appoints, hires and engages Scrips to manage its day-to-day business operations.

 

(c) Scrips, under the
terms and conditions of this Agreement, hereby accepts the appointment and engagement to manage the Pharmacy.

 

    	1

    	 

    

 

2. PURPOSE OF ENGAGEMENT. The general purpose of the
engagement of Scrips is to establish a management structure for the Pharmacy on behalf of Implex. However, the “management
structure” for purposes of this Agreement shall not include any action or activity from which Scrips would be required to
file for, secure and maintain any federal or state license for the purchase, handling, processing and sale of controlled substances,
but shall refer solely to such management as required for the day-to-day business operations of the Pharmacy. In the event of any
confusion, reference is made to the limitations on Implex contained in the stock purchase agreement. Pending Implex’s purchase
of the ownership interest in Pharmacy, Dmitriy Naydenko shall continue the responsibilities for which a license is required, pending
Implex establishing its own structure and control of such activities and obtaining all necessary licenses.

 

(b) Scrips shall have no authority or power with respect to
those areas of the business activities of Pharmacy which require federal or state licensure and Scrips shall not interfere with
the management of the compounding pharmacy with respect to those areas.

 

3. NATURE OF ENGAGEMENT. (a) Scrips shall report to,
act under the authority of, and follow the directives of, Implex as the owner of Pharmacy and Implex shall have full authority
to direct the management of Pharmacy.

 

(b) The parties are separate corporate entities. Nothing in
this Agreement is intended to form a partnership, joint venture, other entity or profit-sharing arrangement among the parties,
nor, except as otherwise specifically provided, to give any party an interest in the assets, business, profits, losses, liabilities,
obligations, and/or revenues of the other.

 

(c) Scrips is an independent contractor and shall be responsible
for the conduct of management by its own employees, consultants and agents. Scrips shall be responsible for its own taxes, including
payroll taxes, and all other costs and liabilities associated with its operations and its management of Pharmacy.

 

4. TERM. (a) The initial term of this Agreement shall
be from February 7, 2014 to January 31, 2019, unless sooner terminated pursuant to Paragraph 9 below.

(b) If, at September 30, 2018 this Agreement is still in effect,
and Scrips is not in default under this Agreement, then Scrips shall have the option to continue this Agreement and relationship
for a further term of five (5) years; i.e., from February 1, 2019 to January 31, 2024.

 

5. DUTIES OF SCRIPS. (a) Upon the Initial Closing by
Implex of its stock purchase agreement, Implex shall notify Scrips of such and thereupon Scrips shall assume the management of
Pharmacy, including the financial management. Scrips shall provide the funds, to the extent necessary, to pay all costs and expenses
incurred in the operation of the Pharmacy, including but not limited to labor, payroll taxes, fringe benefits, insurance repairs,
maintenance and professional fees, as well as all financing costs and debt service pertaining to the financing obtained for operation
of the Pharmacy, including specifically accounts receivable financing. Scrips shall open a bank account for Pharmacy, in the name
of Pharmacy, which Scrips shall control but to which Implex shall have signature authority and access. Scrips shall, from time
to time, in addition to the regular deposits of the funds of Pharmacy, when such deposits are inadequate, deposit such of its own
funds as advances or loans, to Pharmacy, as necessary or desirable for the timely payment of Pharmacy’s payables. Scrips,
from time to time, as available cash and timing permit, shall withdraw up to such amounts in repayment of its loans and advances
as Scrips shall determine. In general, Scrips shall be responsible for the timely cash management of Pharmacy.

 

    	2

    	 

    

 

(b) Scrips shall manage and supervise the operation of Pharmacy,
in the name of Pharmacy, including, but not limited to:

(i) hiring, firing, training, supervising, setting pay
scales for and paying, all required Pharmacy personnel;

(ii) hiring, firing, supervising, negotiating pay and
commission scales for, and paying, all required sales and marketing personnel;

(iii) establishing and enforcing personnel, safety,
controlled substance and environmental policies;

(iv) determining and establishing sources for products
and inventory needed for the operation of the Pharmacy and purchasing of same;

(v) establishing and applying quality controls on the
output of the compounding Pharmacy;

(vi) maintaining, repairing, refurbishing and replacing
all Pharmacy equipment, machinery, vehicles, fixtures, and leasehold improvements;

(vii) assisting Pharmacy and Implex in applying for,
obtaining, re-applying for, and retaining all licenses, permits and other authorizations required for operation of the Pharmacy
as a compounding pharmacy;

(viii) establishing, applying and
enforcing all governmental workplace safety (e.g. OSHA) and environmental regulations and requirements;

(ix) insuring the Pharmacy, and all of its equipment,
machinery, vehicles, fixtures, and leasehold improvements against damage or loss to the extent required by all lenders, but not
less than full market value; and

(x) maintaining the Pharmacy and the security thereof.

 

6. OWNER’S DRAWS. (a) Implex shall be entitled
to draw certain amounts, each month, commencing April 1, 2014 and continuing for the term of this Agreement, which amounts shall
either be paid over to Implex or paid to such persons and/or entities as Implex may direct. Such amounts shall be an Allowable
Deduction for purposes of calculating the Management Fee payable to Scrips pursuant to Paragraph 7 following.

 

(b) Commencing April 1, 2014 and continuing to, and including,
March 1, 2015, Implex shall be entitled to a monthly draw calculated as the total of (i) $26,654.44, (ii) $7,160.64, (iii) $13,187.88
and (iv) a sum calculated as $30 per prescription processed by the Pharmacy during the preceding month, except that the payment
for April 1, 2014 shall include all prescriptions processed since the First Closing by Implex.

 

(c) Commencing April 1, 2015 and continuing to, and including,
March 1, 2016, Implex shall be entitled to a monthly draw calculated as the total of (i) $7,160.64, (ii) $ 1,666.66 and (iii),
subject to sub-paragraph (e) following, a sum calculated as $30 per prescription processed by the Pharmacy during the preceding
month.

 

(d) Commencing April 1, 2016 and continuing thereafter, Implex
shall be entitled to a monthly draw calculated as $30 per prescription processed by the Pharmacy during the preceding month.

 

(e) At such time as the Pharmacy shall have processed 10,000
prescriptions, the sum to be paid shall be reduced, commencing with the 10,001st prescription, to $10 per prescription
instead of $30.

 

    	3

    	 

    

 

7. COMPENSATION OF SCRIPS. In consideration for SCRIPS
providing (i) the financing of the day-to-day operations of Pharmacy and (ii) its management services hereunder, Pharmacy shall
pay to SCRIPS a combined Financing Fee (including interest on all funds advanced or loaned) and Management Fee in an amount calculated
as ninety-seven percent (97%) of the Calculation Basis as defined herein (“Fee”). The Fee shall be calculated monthly
based upon the data from the preceding calendar month. The “Calculation Basis” is Pharmacy’s total receipts from
paid invoices during the preceding calendar month (i.e., total revenue on a cash basis) less the Allowable Deductions as
defined herein. The “Allowable Deductions” shall consist of (i) the owner’s draw as provided in Paragraph 6 above,
(i) the purchase cost of the pharmaceutical products sold during the preceding calendar month, together with the related in-bound
freight and out-bound delivery costs, and the warehousing and storage costs allocated for such sold products, (iii) rent, CDR salary
per employment agreement, salesmen’s commissions and all other reasonable overhead and operating costs such as telephone,
utilities, office supplies, travel and entertainment, etc., but shall exclude (iii) interest, (iv) income taxes, and (v) depreciation/amortization
and other non-cash deductions. The Fee calculated for each month’s Calculation Basis shall be drawn from the Pharmacy account
described in Paragraph 5(a) at such times as Scrips shall determine, given Scrips’ responsibility for the tiomely cash management
of the Pharmacy. There shall be no carryback nor carryforward from month to month and no loss shall be distributed to SCRIPS. In
the event of a subsequently discovered error or discrepancy, the parties shall true-up the data and adjust currently for the prior
underpayment or overpayment. Any true-up shall be only with respect to correction of any data relied upon at the time of the calculation
and payment of the Fee for any month.

 

8. BOOKS AND RECORDS. Scrips, at its sole expense, shall
maintain separate and complete books and records, on the appropriate accrual basis, in accordance with sound and generally accepted
accounting principles (which, having been adopted, shall not be changed without unanimous consent of the parties) showing all revenues,
sales, receipts, costs, expenses, liabilities, receivables, profits and losses. Implex and Pharmacy shall have full access, during
normal business hours, to all such books and records and the supporting documentation therefor.

 

9. REPORTS AND TAX REPORTS. (a) Promptly after each fiscal
year, such accountant as Scrips may, from time to time, appoint, shall prepare such financial reports of Pharmacy from the books
which it keeps, as would be required for delivery to an auditor for audit purposes and deliver copies thereof to Implex and Pharmacy.
Such financial statements shall be at the expense of Scrips.

(b) The accountant appointed by Scrips shall also prepare a
tax return and constituent schedules for Pharmacy for the fiscal year then ended, for use by Implex in filing a consolidated tax
return to the IRS. The costs and expenses of such preparation will be borne by Scrips.

 

10. TERMINATION. This Agreement may be terminated by
any of the parties as follows:

(a) Upon failure of the other party to cure
a default under, or a breach of, this agreement within thirty (30) days after written notice is given as to such default or breach
by the terminating party;

(b) Upon the bankruptcy or liquidation of
the terminated party; whether voluntary or involuntary;

(c) Upon the terminated party taking the
benefit of any insolvency law; and/or

(d) Upon the termionated party having, or
applying to have, a receiver appointed for all or a substantial part of such party's assets or business.

 

    	4

    	 

    

 

MISCELLANEOUS

 

10. Should a party default in the terms or conditions of this
Agreement and suit be filed as a result of such default, the prevailing party shall be entitled to recover all costs incurred as
a result of such default including all costs and reasonable attorney fees, expenses and court costs through trial and appeal.

 

11. The failure of either party to object to, or to take affirmative
action with respect to, any conduct of another party which is in violation of the terms of this Agreement shall not be construed
as a waiver of such violation or breach, or of any future breach, violation, or wrongful conduct. No delay or failure by any party
to exercise any right under this Agreement, and no partial or single exercise of that right, shall constitute a waiver of that
or any other right, unless otherwise expressly provided herein.

 

12. The rights and obligations of the parties under this Agreement
shall inure to the benefit of, and shall be binding upon, the successors and assigns of the parties. This Agreement may not be
assigned by any party or by operation of law or otherwise, except by the express prior written consent of the other parties.

 

13. All notices or other communications to be sent as provided
for in this Agreement shall be in writing and shall be sent by certified mail, postage prepaid, to the persons and addresses herein
designated or such other persons and/or addresses as may hereafter be designated in writing by the parties:

 

If to Pharmacy:

 

If to Scrips:

 

If to Implex:

 

A copy of any notice may be sent by e-mail or fax, but shall
not be deemed served until three (3) days after the date of mailing.

 

14. This instrument contains the entire agreement of the parties
and all prior negotiations, memoranda, understandings and interim agreements have been merged herein. It may be modified only by
an amendment in writing, signed by the party against whom enforcement of any waiver, change, modification, extension or discharge
is sought. No representations were made or relied upon by any party other than those expressly set forth in this Agreement.

 

    	5

    	 

    

 

15. If any provision of this Agreement is declared void, such
provision shall be deemed severed from this Agreement, which shall otherwise remain in full force and effect.

 

16. This Agreement shall be a contract made in the State of
New Jersey and shall be interpreted and governed by, and construed in accordance with, the laws of the State of New Jersey.

 

17. Any and all taxes, excises, assessments, levies, interest
and penalties, which may be assessed, levied, demanded, or imposed by any governmental agency in connection with this Agreement,
shall be paid by the party upon which they are imposed and shall be the sole obligation of such party.

 

18. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties hereto,
intending to be legally bound, have executed this Agreement.

 

MAIN AVENUE PHARMACY, INC..

 

 

By:  /s/ Dmitriy Naydenko 

        Dmitriy Naydenko, Pres

 

SCRIPSAMERICA, INC.

 

 

By:  /s/ Robert Schneiderman 

        Robert Schneiderman, Pres

 

IMPLEX CORPORATION

 

 

By:  /s/ Richard C. Fox 

        Richard C. Fox, Pres

 

 

 

    	6Exhibit 10.25

 

WORLDWIDE LICENSING AGREEMENT

 

 

 

This agreement (“Agreement”)
is between SCRIPSAMERICA, INC. (“Licensor”), a corporation doing business at CORPORATE OFFICE CENTRE TYSONS IL 1650
TYSONS BOULEVARD, SUITE 1580, TYSONS CORNER, ZIP 22102 in the State of VIRGINIA and GLOBAL PHARMA HUB (“Licensee”), a
corporation doing business at 200 SOUTH KNOWLES AVENUE, WINTER PARK, ZIP 32789 in the State of FLORIDA for a license to market
and distribute RapiMed products.

 

A description of RapiMed
is as follows:

 

The target market for
RapiMed is all OTC and prescription drugs, and we anticipate great success because our of our its NEW oral delivery technology
(ODT) that is more effective than existing products due to its ability to melt faster, taste better and provide more accurate dosing.

 

Unlike other products
available, ScripsAmerica’s initial pediatric remedy is much smaller and dissolves in the child's mouth in 25 seconds, therefore
entering their system faster. RapiMed for children's pain and fever relief contains Acetaminophen (main ingredient in Tylenol),
however the bitter taste of this active ingredient is masked. The cherry and wild grape flavors that our product will come in are
most appealing to children. Additionally, RapiMed for children pain and fever reliefs dosage is controlled, not like the syringe
based competing products and we offer the 80 mg for 2-6 year olds, and 160 mg for the 6-11 year olds.

 

RapiMed's children's pain
and fever relief packaging is convenient, portable, child resistant and easy to use as well as eye-catching. The contents are aspirin
free, ibuprofen free, sugar free and gluten free as well. Since the numerous Tylenol recalls in the recent past, there is a clear
need for a better controlled, more efficient product to fill the void. We believe our RapiMed for children's pain and fever relief
is that product.

 

www.rapimeds.com

 

Trade-marks that Fall Under the License Agreement:

 

Trademark:RAPIMED

Class:OOS

Our ref.: 77722

 

Trademark: MELTS IN YOUR CHILD'S MOUTH

Trademark Serial Number: 85932286

USPTO Number: 4472782

    	1

    	 

    

 

In consideration of the
foregoing premises and the mutual covenants set forth in this agreement and other valuable considerations, the parties agree as
follows:

 

1. License: Licensor
hereby grants Licensee the Exclusive Worldwide License, excluding the territory of the United States of America ("United States"),
to use RapiMed Products for the permitted uses as set forth in this agreement only. All other rights in and to the Products, including
but not limited to all copyright and other intellectual property rights relating to the Product are retained by Licensor.

 

2. Permitted Uses: Licensee may only
use the Product as follows:

 

	A.		Licensee may display Product either physically or electronically;

 

	B.		Licensee may extract or use information contained in Product for educational or research
purposes, including extraction and manipulation of information for the purpose of illustration, explanation, example, comment,
criticism, teaching, research, or analysis;

 

	C.		licensee may enter into marketing and distribution contracts with third party companies
outside of United States;

 

	D.		licensee may enter into distribution agreements with online distributors, as long
as on-line distribution does not enter into United States;

 

	E.		Licensee may, in conjunction with and approval from Licensor, utilize the RapiMed
ODT in other product formulation categories provided by the licensor besides Acetaminophen. These product formulation categories
may include Vitamins, Minerals, Over-the-Counter and Prescription applications;

 

	F.		licensee may enter into sub-license agreements with third parties for the purpose
of market expansion and revenue generation.

 

	G.		All license fees collected by the Licensee from any third party shall be paid as follows:

	1.		percent of the total fees collected will be paid to licensor

	2.		The remaining 75 percent of fees collected will be retained by the licensee

 

3. Prohibited Uses: Licensee is prohibited
from the use of Product not expressly permitted in the preceding section. Prohibited uses include but are not limited to:

 

	A.		Using any aspect of the Product as part of a trade-mark, design-mark, and trade name;

 

    	2

    	 

    

 

	B.		Incorporating the Product in any way that results in a re-distribution or reuse of
the Product or is otherwise made available in a manner such that a third party can extract or access or reproduce Product;

 

	C.		Using the Product in a manner that is considered under applicable law to be infringing,
defamatory or libelous in nature, or that would be reasonably likely cause any person or property reflected in the Product to
be·seen in a false light;

 

	D.		Removing any notice of copyright, trade-mark or other proprietary right from any place
where it is on or embedded in the Product;

 

	E.		Engaging in sales of RapiMed, both physical and on-line, in the territory of the United
States;

 

4. Term: The grant of this license is
effective as of the signing of this agreement for a period of three (3) years and shall renew automatically for additional one
(1) year periods unless terminated by one of the parties with ninety (90) days notice. . The license may be terminated without
notice from licensor if at any time licensee fails to comply with any of its terms of use as stated in this agreement. Upon termination,
Licensee must immediately cease all use of Product and if requested, confirm to Licensor in writing compliance with these requirements.

 

5. Minimum Quotas:

 

During the first 12 months after the Effective
Date herein the Licensee will deliver to the licensor a minimum dollar value of orders in excess of $500,000 of the licensor's
Pediatric RapiMed product.

 

During the following
12 months after the effective date herein the Licensee will deliver to the Licensor a minimum dollar value of orders in excess
of $1,400,000 of the Licensor's Pediatric RapiMed product.

 

During the following
12 months after the effective date herein the licensee will deliver to the Licensor a minimum dollar value of orders in excess
of $2,400,000 of the licensor's Pediatric RapiMed product.

 

Failure to comply with
the stated minimums shall be grounds for termination of the license by the Licensor. Notice of termination with 10 days notice
will be delivered by mail from the Licensor to the licensee via U S mail with a return receipt proof of delivery.

 

The quotas commence 90 days after the acceptance
of the registration (the Effective Date) in Hong Kong, China of the licensor's Pediatric RapiMed product.

 

    	3

    	 

    

 

6. Warranties:
Licensor grants no rights and makes no warranties regarding the use of names, people, trademarks, trade dress, patented or copyrighted
designs or works of art or architecture or other forms of intellectual property represented in any Product.

 

THE PRODUCT IS PROVIDED
"AS IS" WITHOUT REPRESENTATION, WARRANTY OR CONDITION OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED
TO THE IMPLIED REPRESENTATIONS, WARRANTIES OR CONDITIONS OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. LICENSOR DOES
NOT REPRESENT OR WARRANT THAT THE PRODUCT WILL MEET LICENSEE'S REQUIREMENTS OR THAT ITS USE WILL BE UNINTERRUPTED OR ERROR FREE.
THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE PRODUCT IS WITH THE MANUFACTURER AND LICENSOR. SHOULD THE PRODUCT PROVE
DEFECTIVE, MANUFACTURER AND LICENSOR ASSUMES THE ENTIRE RISK AND COST OF ALL NECESSARY CORRECTIONS.

 

7. Indemnification:
Each party shall indemnify, assume the defense of, and hold harmless the other party and its directors, officers, employees, and
agents from every claim, loss, damage, injury, expense (including attorney's fees), judgment, and liability of every kind, nature,
and description arising in whole or in part from the indemnifying party's negligent, fraudulent, or illegal acts or omissions except,
as to the party requesting indemnification, to the extent such Liability results in whole or in part from the unauthorized, negligent,
fraudulent, or illegal act or omission of the party requesting indemnification.

 

8. Amendments to License:
This license may only be amended by a writing signed by Licensee and authorized by Licensor.

 

9. Legal Disputes: This Agreement has been negotiated and
is being contracted for in the State of Delaware. It shall be governed by and interpreted in accordance with the laws of the State
of Delaware, regardless of any conflict-of-law provision to the contrary. In any dispute arising out of or connected with this
Agreement, each party consents to the exclusive jurisdiction of the courts of the State of Delaware or the federal district court
for Delaware; each Party consents to the personal jurisdiction of such courts; and each Party waives any objection to personal
jurisdiction or venue.

 

The parties waive any
right to argue conflict of law principles. The Parties agree that any claim or dispute between them or against any agent, employee,
successor, or assign of the other, whether related to this agreement or otherwise, and any claim or dispute related to this agreement
shall be first taken to mediation. If mediation efforts prove unsuccessful, the parties dispute moves to Federal District Court
of Delaware. Any award of the court may be entered as a judgment in any court of competent jurisdiction. Further, should either
party, successor or assign of either party bring leading proceedings in connection with this agreement the party or parties prevailing
in such proceeding shall be entitled to their reasonable attorney's fees and costs from the non-prevailing party in addition to
any other such relief as may be granted.

 

10. Non-waiver: No failure or neglect
of either party hereto in any instance to exercise any right, power or privilege under this agreement or under applicable law
shall constitute a waiver of any other right, power or privilege in any other instance. All waivers by either party must be in
wiring and signed by the party to be charged.

 

    	4

    	 

    

 

11. Entire Agreement: This Agreement contains the entire
agreement and understanding between the parties and supersedes any prior or contemporaneous written or oral agreements, representations
and warranties between them respecting the subject matter of this Agreement. This Agreement may be amended only by a writing signed
by Licensee and by a duly authorized representative of the Licensor. If any term, provision, covenant or condition of this Agreement,
or the application to any person, place or circumstance, shall be held to be invalid, unenforceable or void, the remainder of this
Agreement and such term, provision, covenant or condition as applied to other persons, places and circumstances shall remain in
full force and effect.

 

12. Confidentiality.

 

Licensee acknowledges
that it may have access to confidential information regarding the Licensor and its business. Licensee agrees that it will not,
during or subsequent to the term of this Agreement, divulge, furnish or make accessible to any person (other than with the written
permission of Licensor) any knowledge or information or plans of Licensor with respect to Licensor or its business, including,
but not by way of limitation, the products of the Licensor, whether in the concept or development stage, or being marketed by Licensor
on the effective date of this Agreement or during the term hereof.

 

13. Covenant Not To Compete.

 

During the term of this Agreement, Licensee
warrants, represents and agrees that it will not directly participate in the information developed for and by Licensor, and will
not compete directly with Licensor in Licensor 's primary industry or related fields.

 

By signing this agreement the parties acknowledges
they have read the entire agreement and fully understand the terms, conditions and obligations of this agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]